Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res. 2018; 122:1439-1459. doi: 10.1161/CIRCRESAHA.117.311588
Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: A review of principal cardiovascular outcome results of EMPAREG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care. 2017; 40:821-831. doi: 10.2337/dc17-0291
Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? reflections from a diabetes care editors' expert forum. Diabetes Care. 2018; 41:14-31. doi: 10.2337/dci17-0057
Suissa S. Mortality reduction in EMPA-REG OUTCOME Trial: Beyond the antidiabetes effect. Diabetes Care. 2018; 41:219-223. doi: 10.2337/dc17-1059
Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, George JT, Zinman B; EMPAREG OUTCOME Investigators. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol. 2018; 71:364-367. doi: 10.1016/j.jacc.2017.11.022
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: Results from the LEADER randomized trial [published online June 13, 2018]. Diabetes Care. doi: 10.2337/dc17-1825
Bethel MA, Patel RA, Merrill P, et al; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis. Lancet Diabetes Endocrinol. 2018; 6:105-113. doi: 10.1016/S2213-8587(17)30412-6
Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017; 60:1862-1872. doi: 10.1007/s00125-017-4370-8
